Eliquis, Jardiance, and Stelara are among the first of 10 different drugs that are now subject to Medicare price negotiations following the passing of the Inflation Reduction Act.
The list includes Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp. Shares of the drugmakers were little changed in the premarket session Tuesday. Bristol Myers was up 0.5%, Eli Lilly gained 0.2%, Johnson & Johnson declined 0.2%, Merck was flat, American depositary receipts of AstraZeneca dropped 0.5%, American depositary receipts of Novartis were down 0.1%, Amgen slipped 0.1%, AbbVie declined 0.5% and American depositary receipts of Novo Nordisk were flat.
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше: